Analysis of risk factors for recurrence after the withdrawal of ASMs in 135 children with epilepsy.

IF 2 4区医学 Q3 CLINICAL NEUROLOGY

Epilepsy Research Pub Date : 2025-08-06 DOI:10.1016/j.eplepsyres.2025.107638

Yuchen Gao, Xuan Li, Zenghua Yong, Baoqiang Yuan, Yunlong Dou

{"title":"Analysis of risk factors for recurrence after the withdrawal of ASMs in 135 children with epilepsy.","authors":"Yuchen Gao, Xuan Li, Zenghua Yong, Baoqiang Yuan, Yunlong Dou","doi":"10.1016/j.eplepsyres.2025.107638","DOIUrl":null,"url":null,"abstract":"Objective: To identify risk factors for seizure recurrence following anti-seizure medication (ASM) withdrawal in children with epilepsy who achieved sustained seizure freedom.Methods: This retrospective cohort study analyzed 135 children with epilepsy from a single tertiary center (2022--2023) meeting withdrawal criteria (aged <16 years, seizure-free ≥2 years on stable ASMs, followed ≥1 year after withdrawal). Participants were grouped by postwithdrawal seizure relapse status: recurrent (n = 42) and nonrecurrent (n = 93). Thirteen risk factors were compared via chi-square tests. Variables significantly associated (P < 0.05) with recurrence in univariate analysis were entered into multivariate logistic regression to identify independent predictors (reported as ORs with 95 % CIs). The analyses were performed with SPSS 19.0.Results: The overall recurrence rate was 31.11 % (42/135), with 80.95 % of recurrences occurring during ASM tapering or within the first year after withdrawal. Univariate analysis revealed significant differences between the recurrence and nonrecurrence groups regarding prewithdrawal EEG abnormalities (P = 0.006), ASM polytherapy (P = 0.003), time to seizure freedom > 1 year (P = 0.037), pretreatment epilepsy duration > 1 year (P = 0.011), presence of comorbidities (P < 0.001), and multiple seizure types (P = 0.020). Multivariate logistic regression confirmed three independent risk factors for recurrence: (1) abnormal EEG before withdrawal (OR=9.268, 95 % CI: 2.255-38.092, P = 0.002), (2) ASM polytherapy (OR=3.205, 95 % CI: 1.159-8.866, P = 0.025), and (3) pretreatment epilepsy duration > 1 year (OR=5.363, 95 % CI: 1.781-16.150, P = 0.003).Conclusion: Abnormal EEG before withdrawal, polytherapy, and pretreatment duration > 1 year predicted recurrence. Enzyme-induction patterns showed exploratory associations requiring further validation.","PeriodicalId":11914,"journal":{"name":"Epilepsy Research","volume":"218 ","pages":"107638"},"PeriodicalIF":2.0000,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epilepsy Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.eplepsyres.2025.107638","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To identify risk factors for seizure recurrence following anti-seizure medication (ASM) withdrawal in children with epilepsy who achieved sustained seizure freedom.

Methods: This retrospective cohort study analyzed 135 children with epilepsy from a single tertiary center (2022--2023) meeting withdrawal criteria (aged <16 years, seizure-free ≥2 years on stable ASMs, followed ≥1 year after withdrawal). Participants were grouped by postwithdrawal seizure relapse status: recurrent (n = 42) and nonrecurrent (n = 93). Thirteen risk factors were compared via chi-square tests. Variables significantly associated (P < 0.05) with recurrence in univariate analysis were entered into multivariate logistic regression to identify independent predictors (reported as ORs with 95 % CIs). The analyses were performed with SPSS 19.0.

Results: The overall recurrence rate was 31.11 % (42/135), with 80.95 % of recurrences occurring during ASM tapering or within the first year after withdrawal. Univariate analysis revealed significant differences between the recurrence and nonrecurrence groups regarding prewithdrawal EEG abnormalities (P = 0.006), ASM polytherapy (P = 0.003), time to seizure freedom > 1 year (P = 0.037), pretreatment epilepsy duration > 1 year (P = 0.011), presence of comorbidities (P < 0.001), and multiple seizure types (P = 0.020). Multivariate logistic regression confirmed three independent risk factors for recurrence: (1) abnormal EEG before withdrawal (OR=9.268, 95 % CI: 2.255-38.092, P = 0.002), (2) ASM polytherapy (OR=3.205, 95 % CI: 1.159-8.866, P = 0.025), and (3) pretreatment epilepsy duration > 1 year (OR=5.363, 95 % CI: 1.781-16.150, P = 0.003).

Conclusion: Abnormal EEG before withdrawal, polytherapy, and pretreatment duration > 1 year predicted recurrence. Enzyme-induction patterns showed exploratory associations requiring further validation.

查看原文本刊更多论文

135例癫痫患儿停药后复发危险因素分析。

目的：探讨癫痫患儿抗癫痫药物停药后癫痫复发的危险因素。方法：本回顾性队列研究分析了来自单一三级中心（2022- 2023）的135例符合停药标准的癫痫患儿（年龄）。结果：总复发率为31.11 %(42/135)，其中80.95 %的复发发生在ASM逐渐减少或停药后一年内。单变量分析发现复发之间的显著差异,但组织关于prewithdrawal脑电图异常(P = 0.006),ASM polytherapy (P = 0.003),发作时间自由> 1年(P = 0.037),预处理癫痫持续时间> 1年(P = 0.011),出现并发症(P  1年(或= 5.363,95 % CI: 1.781 - -16.150, P = 0.003)。结论：停药前、多药前、预处理时间> 1年脑电图异常预测复发。酶诱导模式显示探索性关联，需要进一步验证。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Epilepsy Research 医学-临床神经学

CiteScore

0.10

自引率

4.50%

发文量

143

审稿时长

62 days

期刊介绍： Epilepsy Research provides for publication of high quality articles in both basic and clinical epilepsy research, with a special emphasis on translational research that ultimately relates to epilepsy as a human condition. The journal is intended to provide a forum for reporting the best and most rigorous epilepsy research from all disciplines ranging from biophysics and molecular biology to epidemiological and psychosocial research. As such the journal will publish original papers relevant to epilepsy from any scientific discipline and also studies of a multidisciplinary nature. Clinical and experimental research papers adopting fresh conceptual approaches to the study of epilepsy and its treatment are encouraged. The overriding criteria for publication are novelty, significant clinical or experimental relevance, and interest to a multidisciplinary audience in the broad arena of epilepsy. Review articles focused on any topic of epilepsy research will also be considered, but only if they present an exceptionally clear synthesis of current knowledge and future directions of a research area, based on a critical assessment of the available data or on hypotheses that are likely to stimulate more critical thinking and further advances in an area of epilepsy research.